Design throughput became a public utility. Physical capacity became the moat.
In Q3 2026, the automated laboratory moved onto public balance sheets. NSF committed $380 million to 20 AI-programmable cloud lab teams on July 22. DOE's EMSL ordered a $47 million, 97-instrument autonomous lab. Seattle institutions put $95 million into a closed design-build-test loop. Over the same three months, Ginkgo Bioworks reported revenue down 48% while describing the largest autonomous lab in the world, and Twist Bioscience, Lonza and Samsung Biologics all grew and raised guidance. On August 7, a federal court enjoined WuXi AppTec's 1260H designation, which moved the BIOSECURE decision to OMB and left the December 18 deadline standing.
Robotics rises from 3/5 to 4/5 on federal funding of autonomous labs (NSF, July 22; DOE EMSL, August 5). Quantum falls from 3/5 to 2/5: no biology-relevant result landed in the quarter, and IBM's July 30 advantage claim was in materials, on a problem IBM says suited the hardware.
The automated lab moved onto public balance sheets.
Until this quarter, automated biology was a private asset. Ginkgo built Nebula with shareholder money. Emerald Cloud Lab sold access by subscription. Recursion ran its own imaging farm. In Q3 2026, three separate public and philanthropic commitments reversed that pattern inside ten weeks, and the organizations that built the robots are now selling them to the state rather than to industry.